Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071957 | 0.85 | BACE1 (0.33) | BACE1 | |
| SCHEMBL31072020 | 0.85 | BACE1 (0.31) | BACE1 | |
| SCHEMBL21767543 | 0.85 | BACE1 (0.33) | BACE1 | |
| SCHEMBL21767379 | 0.85 | BACE1 (0.31) | BACE1 | |
| SCHEMBL21767383 | 0.81 | OPRL1 (0.34) | OPRL1 | |
| SCHEMBL31071960 | 0.81 | OPRL1 (0.34) | OPRL1 | |
| SCHEMBL31071940 | 0.81 | OPRL1 (0.33) | OPRL1BACE1 | |
| SCHEMBL21767694 | 0.81 | OPRL1 (0.33) | OPRL1BACE1 | |
| SCHEMBL21780606 | 0.80 | HTR2B (0.37) | — | |
| SCHEMBL1345745 | 0.75 | ATM (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | OPRL1 1633/4885BACE1 446/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | OPRL1 1590/4885BACE1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.